John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

European markets are expected to start the week on a mostly positive note Monday, with all eyes on Tuesday’s presidential ...

Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...